Publications by authors named "Joan Sopczynski"
Article Synopsis
- The study aimed to analyze real-world data to determine how age and treatment (specifically etanercept for rheumatoid arthritis) affect the risk of four common adverse events in older patients.
- Researchers used data from the IBM Watson Health MarketScan Database, focusing on patients aged 18 and older who had no prior history of the four adverse events before starting treatment.
- Results showed that while the overall risk of these adverse events increased with age, the relative risk associated with etanercept was similar for both older (over 65 years) and younger patients (65 years or younger).
